Natural HLA class I ligands from glioblastoma: Extending the options for immunotherapy

Marian Christoph Neidert, Oliver Schoor, Claudia Trautwein, Nico Trautwein, Lisa Christ, Arthur Melms, Jürgen Honegger, Hans-Georg Rammensee, Christel Herold-Mende, Pierre-Yves Dietrich & Stefan Stevanović
Objective: Glioblastoma multiforme (GBM) is the most frequent and most malignant primary brain tumor with a poor prognosis despite surgical removal and radio-chemotherapy. In this setting, immunotherapeutic strategies have great potential, but the reported repertoire of tumor-associated antigens (TAAs)[for full text, please go to the a.m. URL]